Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
66.42 (1y: +25%)
Market Cap 4.03 B P/E(ttm) 55.00
Enterprise Value 4.08 B P/B 7.30
SLXP- NAS (USA)
Salix Pharmaceuticals, Ltd.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$66.42
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.776
SLXP's Cash to Debt is ranked higher than
56% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. SLXP: 0.776 )
SLXP' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: 0.78
Equity to Asset 0.299
SLXP's Equity to Asset is ranked lower than
55% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SLXP: 0.299 )
SLXP' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.86
Current: 0.3
0.3
0.86
Interest Coverage 3.9
SLXP's Interest Coverage is ranked higher than
62% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. SLXP: 3.9 )
SLXP' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: 3.9
F-Score: 6
Z-Score: 2.92
M-Score: -4.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 23.40
SLXP's Operating margin (%) is ranked higher than
91% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. SLXP: 23.40 )
SLXP' s 10-Year Operating margin (%) Range
Min: -155.2   Max: 23.4
Current: 23.4
-155.2
23.4
Net-margin (%) 8.7
SLXP's Net-margin (%) is ranked higher than
75% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SLXP: 8.7 )
SLXP' s 10-Year Net-margin (%) Range
Min: -149.1   Max: 16.2
Current: 8.7
-149.1
16.2
ROE (%) 11.5
SLXP's ROE (%) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. SLXP: 11.5 )
SLXP' s 10-Year ROE (%) Range
Min: -208.2   Max: 15.9
Current: 11.5
-208.2
15.9
ROA (%) 3.4
SLXP's ROA (%) is ranked higher than
67% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. SLXP: 3.4 )
SLXP' s 10-Year ROA (%) Range
Min: -126   Max: 9.8
Current: 3.4
-126
9.8
ROC (Joel Greenblatt) (%) 84.10
SLXP's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.40 vs. SLXP: 84.10 )
SLXP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -556.6   Max: 263.1
Current: 84.1
-556.6
263.1
Revenue Growth (%) 25.1
SLXP's Revenue Growth (%) is ranked higher than
96% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SLXP: 25.1 )
SLXP' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 52.8
Current: 25.1
-1.5
52.8
ยป SLXP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SLXP Guru Trades in Q2 2012

Paul Tudor Jones 4,700 sh (New)
Steven Cohen 413,621 sh (+137.06%)
Jim Simons 264,819 sh (+43.83%)
Pioneer Investments 486,237 sh (+21.65%)
Vanguard Health Care Fund 1,554,300 sh (unchged)
NWQ Managers 633,290 sh (-3.54%)
» More
Q3 2012

SLXP Guru Trades in Q3 2012

Joel Greenblatt 36,061 sh (New)
Paul Tudor Jones 11,900 sh (+153.19%)
Steven Cohen 1,032,220 sh (+149.56%)
Vanguard Health Care Fund 1,554,300 sh (unchged)
NWQ Managers 545,744 sh (-13.82%)
Pioneer Investments 402,190 sh (-17.29%)
Jim Simons 177,119 sh (-33.12%)
» More
Q4 2012

SLXP Guru Trades in Q4 2012

Jim Simons 369,919 sh (+108.85%)
Joel Greenblatt 63,399 sh (+75.81%)
Steven Cohen 1,537,964 sh (+49%)
Pioneer Investments 537,900 sh (+33.74%)
Vanguard Health Care Fund 1,754,300 sh (+12.87%)
NWQ Managers Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2013

SLXP Guru Trades in Q1 2013

Vanguard Health Care Fund 2,147,945 sh (+22.44%)
Pioneer Investments 544,300 sh (+1.19%)
Joel Greenblatt Sold Out
Steven Cohen 793,353 sh (-48.42%)
Jim Simons 53,719 sh (-85.48%)
» More
» Details

Insider Trades

Latest Guru Trades with SLXP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.15%$40.472 - $51.37 $ 66.4238%0
Vanguard Health Care Fund 2013-03-31 Add 22.44%0.08%$40.472 - $51.37 $ 66.4238%2147945
Joel Greenblatt 2012-12-31 Add 75.81%0.06%$37.97 - $42.9 $ 66.4263%63399
Joel Greenblatt 2012-09-30 New Buy0.1%$41.92 - $55.65 $ 66.4240%36061
John Paulson 2011-09-30 Sold Out 0.2056%$26.18 - $40.9 $ 66.42101%0
Vanguard Health Care Fund 2011-09-30 Add 55.43%0.09%$26.18 - $40.9 $ 66.42101%1554300
John Paulson 2011-06-30 Add 971.43%0.19%$34.69 - $40.57 $ 66.4276%1500000
George Soros 2011-06-30 Sold Out $34.69 - $40.57 $ 66.4276%0
John Paulson 2011-03-31 New Buy0.01%$31.61 - $48.03 $ 66.4271%140000
George Soros 2011-03-31 Reduce -95.44%$31.61 - $48.03 $ 66.4271%5700
Vanguard Health Care Fund 2010-12-31 New Buy0.22%$35.96 - $48.61 $ 66.4259%850000
George Soros 2010-12-31 Reduce -54.55%0.1%$35.96 - $48.61 $ 66.4259%125000
George Soros 2010-09-30 New Buy0.16%$37.59 - $44.64 $ 66.4261%275000
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Top Ranked Articles about Salix Pharmaceuticals, Ltd.

Weekly CFO Sells Highlight: FII, SLXP, CCK, VCI, WDC, STMP
December 31, 2012
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Federated Investors Inc., Salix Pharmaceuticals Ltd., Crown Holdings Inc., Valassis Communications Inc., Western Digital Corporation and Stamps.com Inc. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 55.40
SLXP's P/E(ttm) is ranked lower than
55% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.30 vs. SLXP: 55.40 )
SLXP' s 10-Year P/E(ttm) Range
Min: 12.27   Max: 103.53
Current: 55.4
12.27
103.53
P/B 7.30
SLXP's P/B is ranked lower than
62% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. SLXP: 7.30 )
SLXP' s 10-Year P/B Range
Min: 1.04   Max: 28.55
Current: 7.3
1.04
28.55
P/S 5.50
SLXP's P/S is ranked lower than
51% of the 654 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. SLXP: 5.50 )
SLXP' s 10-Year P/S Range
Min: 1.28   Max: 19.56
Current: 5.5
1.28
19.56
PFCF 13.70
SLXP's PFCF is ranked higher than
87% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.96 vs. SLXP: 13.70 )
SLXP' s 10-Year PFCF Range
Min: 5.08   Max: 937
Current: 13.7
5.08
937
EV-to-EBIT 23.3
SLXP's EV-to-EBIT is ranked higher than
62% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.43 vs. SLXP: 23.3 )
SLXP' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 99.5
Current: 23.3
10.4
99.5
Shiller P/E 1062.6
SLXP's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: vs. SLXP: 1062.6 )
SLXP' s 10-Year Shiller P/E Range
Min: 805.67   Max: 5491
Current: 1062.6
805.67
5491

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 17.2
SLXP's Price/Net Current Asset Value is ranked higher than
59% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.20 vs. SLXP: 17.2 )
SLXP' s 10-Year Price/Net Current Asset Value Range
Min: 8   Max: 56.7
Current: 17.2
8
56.7
Price/DCF (Projected) 3.1
SLXP's Price/DCF (Projected) is ranked lower than
51% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. SLXP: 3.1 )
SLXP' s 10-Year Price/DCF (Projected) Range
Min: 2.6   Max: 12.4
Current: 3.1
2.6
12.4
Price/Median PS Value 1
SLXP's Price/Median PS Value is ranked higher than
65% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SLXP: 1 )
SLXP' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.9
Current: 1
0.3
2.9
Earnings Yield (Greenblatt) 4.30
SLXP's Earnings Yield (Greenblatt) is ranked higher than
71% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SLXP: 4.30 )
SLXP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 9.7
Current: 4.3
1
9.7
Forward Rate of Return (Yacktman) 0.36
SLXP's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SLXP: 0.36 )
SLXP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.2   Max: 0.6
Current: 0.36
-7.2
0.6

Business Description

Salix Pharmaceuticals, Ltd. incorporated in the state of Delaware. The company is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company's 'search and development' efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. The company's products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by non-invasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, low-volume liquid bowel prep with the effectiveness of high-volume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. Anusol-HC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The company primarily sells its products to pharmaceutical wholesalers. The company uses third party manufacturers to produce its products.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:XP2.Germany
ยป More Articles for SLXP

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: FII, SLXP, CCK, VCI, WDC, STMP Dec 31 2012 
Weekly Guru Bargains Highlights: HMSY, FB, TSU, SLXP, ANR Oct 29 2012 
Value Shop Nuveen Investments Reports Second Quarter Portfolio Aug 19 2011 
Hedge Fund Giant John Paulson Reports Q2 Portfolio Aug 15 2011 
Salix Pharmaceuticals Ltd. (SLXP) President & CEO Carolyn J Logan sells 14,000 Shares Sep 23 2010 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Dec 11 2009 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Dec 02 2009 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Nov 30 2009 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Nov 19 2009 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Nov 13 2009 

More From Our Partners
ViroPharma Up on Takeover Rumors - Analyst Blog Jun 18 2013 - ZACKS
AstraZeneca and NGM Collaborate - Analyst Blog Jun 18 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK